Overview
This is an Open-label ,Multicenter Study to evaluate Long-Term Safety and Efficacy of CM512 in patients with Atopic Dermatitis who have completed treatment in parent CM512 Study.
Eligibility
Inclusion Criteria:
- Have the ability to understand the study and voluntarily sign a written informed consent form (ICF).
- Subjects who have completed the week 18 evaluation in the parent study CM512-101102 or the End of Study(EOS) visit in the parent study CM512-100001.
Exclusion Criteria:
- Not enough washing-out period for previous therapy.
- Any other condition assessed by the investigator that makes participants unsuitable for participation in this study.